Diagnosis of acromegaly and assessment of treatment efficacy when interpreted in conjunction with results from glucose suppression test
Diagnosis of human growth hormone deficiency when interpreted in conjunction with results from growth hormone stimulation test
This test is not intended for use as a screen for acromegaly.
This test has limited value in assessing growth hormone secretion in normal children.
Immunoenzymatic Assay
Growth Hormone Provocative Test
Growth Hormone Stimulation
hGH (Human Growth Hormone)
Human Growth Hormone
Somatotrophic Hormone
Somatotropin
Serum
For assessing growth hormone secretion in normal children, the recommended test is IGFMS / Insulin-Like Growth Factor 1, Mass Spectrometry, Serum.
For acromegaly screening, the preferred test is IGFGP / Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 Growth Panel, Serum.
Patient Preparation: For at least 8 hours, patient should be fasting.
Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Specimen Volume: 0.6 mL
Collection Instructions:
1. If multiple specimens are collected, submit each vial under a separate order.
2. Label specimens appropriately with the corresponding collection times.
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.
0.5 mL
Gross hemolysis | Reject |
Gross lipemia | OK |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 7 days | |
Frozen | 90 days |
Diagnosis of acromegaly and assessment of treatment efficacy when interpreted in conjunction with results from glucose suppression test
Diagnosis of human growth hormone deficiency when interpreted in conjunction with results from growth hormone stimulation test
This test is not intended for use as a screen for acromegaly.
This test has limited value in assessing growth hormone secretion in normal children.
The anterior pituitary secretes human growth hormone (hGH)
Because hGH levels in normal and diseased populations overlap,
Males:
2-<7 years:* 0.05-5.11 ng/mL
7-<12 years:* 0.02-4.76 ng/mL
12-<14 years:* 0.01-6.20 ng/mL
14-<18 years:* 0.02-3.81 ng/mL
> or =18 years: 0.01-0.97 ng/mL
Females:
2-<7 years:* 0.05-5.11 ng/mL
7-<12 years:* 0.02-4.76 ng/mL
12-<14 years:* 0.01-6.20 ng/mL
14-<18 years:* 0.03-5.22 ng/mL
> or =18 years: 0.01-3.61 ng/mL
*Source: Karbasy K, Lin DC, Stoianov A, et al. Pediatric reference value distributions and covariate-stratified reference intervals for 29 endocrine and special chemistry biomarkers on the Beckman Coulter Immunoassay Systems: a CALIPER study of healthy community children. Clin Chem Lab Med. 2016;54(4):643-657. doi:10.1515/cclm-2015-0558
Reference intervals for patients younger than 2 years have not been established.
For International System of Units (SI) conversion for Reference Values, see www.mayocliniclabs.com/order-tests/si-unit-conversion.html
Acromegaly: For suppression testing, normal subjects have a nadir human growth hormone (hGH) concentration below 0.3 ng/mL after ingestion of a 75-gram glucose dose. Patients with acromegaly fail to show normal suppression. Using the Access ultrasensitive hGH assay, a cutoff of 0.53 ng/mL for nadir hGH was found to differentiate patients most accurately with acromegaly in remission from active disease with a sensitivity of 97% (95% CI, 83%-100%) and a specificity of 100% (95% CI, 82%-100%).(1)
Deficiency: A normal response following stimulation tests is a peak hGH concentration above 5 ng/mL in children and above 4 ng/mL in adults. For children, some experts consider hGH values between 5 ng/mL and 8 ng/mL equivocal and only GH peak values greater than 8 ng/mL as truly normal. Low levels, particularly under stimulation, indicate hGH deficiency.
As the human growth hormone (hGH) test has limited value in assessing growth hormone secretion in normal children, IGFMS / Insulin-Like Growth Factor 1, Mass Spectrometry, Serum is recommended as the first test for assessing deficient or excess growth during childhood and adolescent development. IGF1 reference intervals for Tanner stages are available. Suspected causes of dwarfism should be diagnosed with the aid of provocative testing.
Elevated levels of hGH indicate the possibility of gigantism or acromegaly but must be confirmed with stimulation and suppression testing.
Growth hormone is secreted in surges; single measurements are of limited diagnostic value.
1. Bancos I, Algeciras-Schimnich A, Woodmansee WW, et al. Determination of nadir growth hormone concentration cutoff in patients with acromegaly. Endocr Pract. 2013;19(6):937-945. doi:10.4158/EP12435.OR
2. Camacho-Hubner C. Assessment of growth hormone status in acromegaly: what biochemical markers to measure and how? Growth Hormone IGF Res. 2000;10 Suppl B:S125-299
3. Nilsson AG. Effects of growth hormone replacement therapy on bone markers and bone mineral density in growth hormone-deficient adults. Horm Res. 2000;54 Suppl 1:52-57
4. Strasburger CJ, Dattani MT. New growth hormone assays: potential benefits. Acta Paediatr Suppl. 1997;423:5-11
5. Okada S, Kopchick JJ. Biological effects of growth hormone and its antagonist. Trends Mol Med. 2001;7(3):126-132
6. Veldhuis JD, Iranmanesh A. Physiological regulation of human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep. 1996;19(10 Suppl):S221-224
7. Melmed S: Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med. 2019;380(26):2551-2562. doi:10.1056/NEJMra1817346
8. Karbasy K, Lin DC, Stoianov A, et al. Pediatric reference value distributions and covariate-stratified reference intervals for 29 endocrine and special chemistry biomarkers on the Beckman Coulter Immunoassay Systems: a CALIPER study of healthy community children. Clin Chem Lab Med. 2016;54(4):643-657. doi:10.1515/cclm-2015-0558
The instrument used is the Beckman Coulter UniCel DXI 800. The Access ultrasensitive human growth hormone (hGH) assay is a simultaneous one-step immunoenzymatic ("sandwich") assay. A sample is added to a reaction vessel along with polyclonal goat anti-hGH alkaline phosphatase conjugate and paramagnetic particles coated with mouse monoclonal anti-hGH antibody. The patient sample hGH binds to the monoclonal anti-hGH on the solid phase, while the goat anti-hGH-alkaline phosphatase conjugate reacts with a different antigenic site on patient sample hGH. After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then, the chemiluminescent substrate Lumi-Phos 530 is added to the vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of hGH in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve.(Package insert: Access Ultrasensitive hGH Growth Hormone. Beckman Coulter Inc.; 01/2022)
Monday through Friday, Sunday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
83003
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
HGH | Growth Hormone, S | 2963-7 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
HGH | Growth Hormone, S | 2963-7 |
Change Type | Effective Date |
---|---|
Test Changes - Reference Value | 2024-04-23 |